REPORT HIGHLIGHT
Recombinant proteins manufacturing services market size was valued at USD 1,908.6 Million in 2022, expanding at a CAGR of 12.8% from 2023 to 2030.
The recombinant proteins manufacturing services market known as the industry that provides services for the production of recombinant proteins as these proteins are produced through genetic engineering techniques, is also known as gene splicing or recombinant DNA technology. In line with this, recombinants often use microorganisms such as yeast bacteria, or mammalian cells, to produce and express specific proteins of interest. The recombinant DNA is inserted into expression vectors that contain the ribosome binding site, terminator, and promoter. Additionally, these proteins are majorly used in numerous fields, including diagnostics, research, industrial, and biopharmaceutical applications.
Recombinant Proteins Manufacturing Services Market - Market Dynamics:
- The increasing cancer burden is expected to fuel the market growth
- The surge in the cancer burden is expected to drive the demand for recombinant proteins manufacturing services market, as recombinant proteins are widely used in the diagnosis and research of cancer. The increasing burden of cancer creates a requirement for advanced therapeutics and has resulted in increased adoption of outsourcing services for the development of advanced therapies. Additionally, the cost-prohibitive process of producing protein involves specialized facilities and enormous production capabilities. The complexities related to the production of recombinant protein-based products can be increased further by various issues concerning regulatory compliance and adherence to manufacturing standards. Thus, the trending opportunities toward recombinant protein manufacturing services to leverage the capabilities and expertise of CMOs in this domain have been rising in recent years. Moreover, in the biopharmaceutical industry, outsourcing certain specialized and repetitive tasks including analytical testing/bioassays, toxicology testing, and fill/finish is becoming more common. However, the reproducibility of protein production processes and managing the costs associated with manufacturing are likely to hinder the growth of the recombinant proteins manufacturing services market.
Recombinant Proteins Manufacturing Services Market - Key Insights:
- As per the analysis shared by our research analyst, the global recombinant proteins manufacturing services market is estimated to grow annually at a CAGR of around 12.8% over the forecast period (2023-2030)
- The recombinant proteins manufacturing services industry is projected to grow at a significant rate due to the growing prevalence of cancer disease
- Based on service type segmentation, commercial production services was predicted to show maximum market share in the year 2022
- Based on host cell segmentation, mammalian cells was the leading type in 2022
- The advancements in recombinant technology, novel properties of proteins for manufacturing personalized medicine, bioengineering products, and cell & gene therapies are expected to increase.
Recombinant Proteins Manufacturing Services Market- Segmentation Analysis:
- The global recombinant proteins manufacturing services market is segmented on the basis of service type, host cell, end user, and region.
- The market is divided into two categories based on service type: commercial production services and pre-clinical & clinical services. The commercial production services segment is likely to maintain its dominance. The factors driving the commercial production services market such as the development of recombinant DNA technology, protein expression systems, cell culture methods, and growing accessibility of high-yield expression systems include yeast, bacteria, and mammalian cell lines resulting in production productivity & efficiency.
- The market is divided into four categories based on host cells: yeast & fungi, mammalian cells, insect cells, bacterial cells, and others. The mammalian cells segment is likely to possess the largest revenue share. Mammalian cells are appropriate host cells for manufacturing complex recombinant proteins that require subunit assembly, significant folding, and/or posttranslational modifications. These features assist in understanding the preference for mammalian cells used in the pharmaceutical and biotech industries for developing diagnostic and therapeutic proteins.
Recombinant Proteins Manufacturing Services Market- Geographical Insights
North America is projected to hold the largest revenue share of the recombinant proteins manufacturing services market. This can be associated with larger research expenses, the availability of established healthcare infrastructure, and the presence of various industry participants. Thus, above mention factors are projected to raise the demand for recombinant protein manufacturing services. Moreover, Asia Pacific is accounted to experience the fastest growth rate owing to improving economic factors, favorable regulatory policies, improved healthcare infrastructure, and an increase in government efforts to raise awareness will likely boost the adoption rate for recombinant manufacturing services. The region's increasing demand for good-quality healthcare has a beneficial impact on the industry.
Recombinant Proteins Manufacturing Services Market- Competitive Landscape:
Various market opportunities have been created for major players to capitalize on the continuous demand for recombinant protein manufacturing services. The rising requirement for recombinant proteins in research and biopharmaceuticals drives the need for recombinant protein manufacturing services. Additionally, the market trends include using single-use bioreactors for flexible and cost-effective production, a rising focus on sustainable and environmentally friendly manufacturing processes, and advancements in protein engineering and modification techniques. The market is highly competitive with numerous key players and emerging nations providing a range of services. Innovation and improved service offerings are often driven by competition.
Recent Developments:
For instance, in April 2023, the LFB Group introduced its subsidiary LFB BIOMANUFACTURING, which has become a member of the France BioLead association promoting biopharmaceutical production in France. By becoming a member of France BioLead, LFB BIOMANUFACTURING has collaborated with various French players in the sector to put our nation on the map of biomanufacturers of tomorrow's therapeutic innovations.
SCOPE OF THE REPORT
The scope of this report covers the market by its major segments, which include as follows:
GLOBAL RECOMBINANT PROTEINS MANUFACTURING SERVICES MARKET KEY PLAYERS
- Kaneka Corporation
- Lonza
- Boehringer Ingelheim International GmbH
- GenScript
- FUJIFILM Diosynth Biotechnologies
- Sino Biological, Inc.
- Boster Biological Technology
- Merck KGaA
- Polyplus Transfection (Xpress Biologics)
- Trenzyme GmbH
- Bruker (InVivo BioTech Services GmbH)
GLOBALRECOMBINANT PROTEINS MANUFACTURING SERVICES MARKET, BY SERVICE TYPE
- Commercial Production Services
- Pre-clinical & Clinical Services
GLOBAL RECOMBINANT PROTEINS MANUFACTURING SERVICES MARKET, BY HOST CELL
- Yeast & Fungi
- Mammalian Cells
- Insect Cells
- Bacterial Cells
- Others
GLOBAL RECOMBINANT PROTEINS MANUFACTURING SERVICES MARKET, BY END USER
- Academic & Research Institutes
- Pharmaceutical & Biotechnology Companies
GLOBAL RECOMBINANT PROTEINS MANUFACTURING SERVICES MARKET, BY REGION
- Europe
- Germany
- France
- Italy
- Spain
- United Kingdom
- Russia
- Netherlands
- Sweden
- Poland
- Rest of Europe
- Asia Pacific
- India
- China
- South Korea
- Japan
- Australia
- Thailand
- Indonesia
- Philippines
- Rest of APAC
- Latin America
- Brazil
- Mexico
- Argentina
- Colombia
- Rest of LATAM
- The Middle East and Africa
- Saudi Arabia
- United Arab Emirates
- Israel
- Turkey
- Algeria
- Egypt
- Rest of MEA